| 1 |
陈永, 刘文静, 邹峻, 等. 白塞病合并肠道病变的临床回顾性分析 [J]. 复旦学报(医学版), 2017, 44(4): 493-497.
|
| 2 |
Park YE, Cheon JH. Updated treatment strategies for intestinal Behçet's disease [J]. Korean J Intern Med, 2018, 33(1): 1-19.
|
| 3 |
Tanida S, Mizoshita T, Nishie H, et al. Long-term efficacy of adalimumab in patients with intestinal Behcet's disease: eight consecutive cases [J]. J Clin Med Res, 2016, 8(4): 334-337.
|
| 4 |
Wu QJ, Zhang FC, Zhang X. Adamantiades-Behcet's disease-complicated gastroenteropathy [J]. World J Gastroenterol, 2012, 18(7): 609-615.
|
| 5 |
Park JJ, Kim WH, Cheon JH. Outcome predictors for intestinal Behçet's disease [J]. Yonsei Med J, 2013, 54(5): 1084-1090.
|
| 6 |
Kovacs DB, Ray DK, Dasqupta K, et al. Intestinal complications of Behçet's disease [J].BMJ Case Rep, 2013, 2013: bcr2013200253.
|
| 7 |
Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behcet's disease in Korean patients with ileocolnic ulcers [J]. Am J Gastroenterol, 2009, 104(10): 2492-2499.
|
| 8 |
Lee HJ, Shin HS, Jang HW, et al. Correlation between soluble triggering receptor expressed on myeloid cells-1 and endoscopic activity in intestinal Behçet's disease [J]. Yonsei Med J, 2014, 55(4): 960-966.
|
| 9 |
Jun S, Takao K, Erika T, et al. Bifidobacteria abundance-featured gut microbiota compositional Change in patients with Behcet's disease [J]. PloS One, 2016, 11(4): e0153746.
|
| 10 |
Lopalco G, Rigante D, Venerito V, et al. Update on the medical management of gastrointestinal Behçet's disease [J]. Mediators Inflamm, 2017, 2017: 1460491.
|
| 11 |
Kim DH, Cheon JH. Intestinal Behçet's disease: A true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis? [J]. Yonsei Med J, 2016, 57(1): 22-32.
|
| 12 |
Emmi G, Silvestri E, Bella CD, et al. Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-a in early phases of the disease [J].Medicine (Baltimore), 2016, 95(49): e5516.
|
| 13 |
Kim SW, Jung YS, Ahn JB, et al. Identification of genetic susceptibility loci for intestinal Behçet's disease [J]. Sci Rep, 2017, 7: 39850.
|
| 14 |
罗丹, 申艳, 邹峻, 等. Th17/Treg相关细胞因子在肠白塞病发病机制中的作用 [J]. 复旦学报(医学版), 2016, 43(2): 154-158.
|
| 15 |
刘月, 杨艳, 苏芮, 等. 肠道菌群调控白塞病中辅助性T细胞17/调节性T细胞免疫平衡的研究进展 [J]. 中华风湿病学杂志, 2019, 23(8): 558-561.
|
| 16 |
Ahmadi M, Yousefi M, Abbaspour-Aghdam S, et a1. Disturbed Thl7/treg balance, cytokines, and miRNAs in peripheral blood of patients with Behcet'disease [J]. J Cell Physiol, 2019, 234(4): 3985-3994.
|
| 17 |
Imamura Y, Kurokawa MS, Yoshikawa H, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behçet's disease [J]. Clin Exp Immunol, 2005, 139(2): 371-378.
|
| 18 |
孟德钎, 李璐, 刘金晶, 等. 英夫利西单克隆抗体治疗重症/难治性肠型白塞病的疗效分析: 单中心回顾性研究 [J]. 协和医学杂志, 2019, 10(3): 237-242.
|
| 19 |
王媛, 李建国, 周志轩, 等. 胃肠道受累的儿童白塞病临床特点分析 [J]. 中华风湿病学杂志, 2018, 22(11): 744-747.
|
| 20 |
田珂, 王晶桐, 朱元民, 等. 具有消化系统表现的白塞病的临床特点 [J]. 胃肠病学和肝病学杂志, 2014, 23(2): 208-212.
|
| 21 |
Watanabe K, Tanida S, Inoue N, et al. Evidence-based diagnosis and clinical practice guidelines for intestinal Behcet's disease 2020 edited by intractable diseases, the health and labour sciences research grants [J]. J Gastroenterol, 2020, 55(7): 679-700.
|
| 22 |
Vicente CS, Freitas AD. Surgical treatment of intestinal perforation in Behçet syndrome: an unusual presentation [J]. Pan Afr Med J, 2018, 30: 230.
|
| 23 |
Özşeker B, Şahin C, Özşeker HS, et al. The role of fecal calprotectin in evaluating intestinal involvement of Behçet's disease [J]. Dis Mark, 2016, 2016: 5423043.
|
| 24 |
Lee HJ, Cheon JH. Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease [J]. Intest Res, 2017, 15(3): 311-317.
|
| 25 |
Kötter I, Lötscher F. Behçet's syndrome apart from the triple symptom complex: vascular,neurologic, gastrointestinal, and musculoskeletal manifestations [J]. Front Med(Lausanne): 2021, 8: 639758.
|
| 26 |
肖雨, 周炜洵, 王维斌, 等. 肠道贝赫切物综合征的临床病理 [J]. 协和医学杂志, 2012, 3(1): 56-59.
|
| 27 |
Miyagawa I, Nakano K, Iwata S, et al. Comparative study of corticosteroid monotherapy,and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease [J]. Arthritis Res Ther, 2019, 21: 151.
|
| 28 |
宋迪, 毛庆聪, 邵伟新. 肠型白塞病的CT表现 [J]. 医学影像学杂志, 2016, 26(1): 151-153.
|
| 29 |
Li J, Li P, Bai J, et al. Discriminating potential of extraintestinal systemic manifestations and colonoscopic features in Chinese patients with intestinal Behçet's disease and Crohn's disease [J]. Chin Med J(Engl), 2015, 128(2): 233-238.
|
| 30 |
Zhu ZH, Shu X, Long SH, et al. Ulcerative colitis followed by the development of typical intestinal Behçet disease [J]. Medicine (Baltimore), 2018, 97(7): e9882.
|
| 31 |
杨洋, 余叶, 林进. 肠白塞病生物标志物研究进展 [J]. 中华风湿病学杂志, 2021, 25(6): 426-430.
|
| 32 |
Zhang L, Tian Y, Ye JF, et al. Poor prognostic factors in patients with nwely diagnosed intestinal Adamantiades-Behcet's disease in the Shanghai Adamantiades-Behcet's disease database:a prospective cohort study [J]. Orphanet J Rare Dis, 2019, 14(1): 274-284.
|
| 33 |
沈颖, 杨辉, 金玉. 儿童肠型白塞病的诊断和治疗 [J]. 中华儿科杂志, 2019, 57(3): 235-237.
|
| 34 |
Jung YS, Kim SW, Yoon JY, et al. Expression of a soluble triggering receptor expressed on myeloid cells-1(Strem-1) correlates with clinical disease activity in intestinal Behcet's disease [J]. Inflamm Bowel Dis, 2011, 17(10): 2130-2137.
|
| 35 |
Hiregoudar AD, Battal MM, Vishwanath N, et al. Subtotal colectomy for intestinal Behcet's disease:a histopathological surprise [J]. Indian J Surg, 2009, 71(3): 159-161.
|
| 36 |
Kobayashi K, Ueno F, Bito S, et al. Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach [J]. J Gastroenterol, 2007, 42: 737-745.
|
| 37 |
Hisamatsu T, Hayashida M. Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease [J]. Intest Res, 2017, 15(3): 318-327.
|
| 38 |
Kaji M, Kishi T, Miyamae T, et al. Efficacy of adalimumab in a girl with refractory intestinal Behcet's disease [J]. Case Rep Rheumatol, 2015, 2015: 716138.
|
| 39 |
Park J, Cheon JH, Park Y, et al. Efficacy and tolerability of methotrexate therapy for refractory intestinal Behçet's disease:a single center experience [J]. Intest Res, 2018, 16(2): 315-318.
|
| 40 |
Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: indication of anti-TNFα monoclonal antibodies [J]. J Gastroenterol, 2014, 49(1): 156-162.
|
| 41 |
Jung YS, Hong SP, Kim TI, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease [J]. Inflamm Bowel Dis, 2012, 46(5): e38-e45.
|
| 42 |
Jung YS, Cheon JH, Hong SP, et al. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease [J]. Inflamm Bowel Dis, 2012, 18(4): 750-757.
|
| 43 |
Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease [J]. Mod Rheumatol, 2011, 21: 184-191.
|
| 44 |
Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease [J]. Clin Gastroenterol Hepatol, 2015, 13: 940-948,e3.
|
| 45 |
Park J, Cheon JH. Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy? [J]. Intest Res, 2017, 15(3): 263-265.
|
| 46 |
Inoue N, Kobayashi K, Naganuma M, et al. Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial [J]. Intest Res, 2017, 15(3): 395-401.
|
| 47 |
Li Y, Han ZL, Wang XF, et al. Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease:a case report [J]. BMC Gastroenterol, 2013, 13: 167.
|
| 48 |
Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological,and vascular involvement in Behcet disease:Efficacy,safety,and pharmacokinetics in a multicenter,prospective,open-label,single-arm phase 3 study [J]. Medicine (Baltimore), 2016, 9(24): e3863.
|